-
1.发明申请PAI-1 EXPRESSION AND ACTIVITY INHIBITORS FOR THE TREATMENT OF OCULAR DISORDERS 审中-公开PAI-1表达和活化抑制剂治疗眼病公开(公告)号：US20090202524A1
公开(公告)日：2009-08-13
申请号：US12421456
申请日：2009-04-09
IPC分类号： A61K31/40 , A61K31/366 , A61K31/404 , A61K39/395
CPC分类号： A61K31/404 , A61K31/19 , A61K31/192 , A61K31/22 , A61K31/277 , A61K31/353 , A61K31/366 , A61K31/403 , A61K31/41 , A61K31/416 , A61K31/437 , A61K31/4436 , A61K31/4439 , A61K31/4965 , A61K31/497 , A61K38/16
摘要： The invention concerns in one embodiment a method for treating glaucoma or elevated IOP in a patient comprising administering to the patient an effective amount of a composition comprising an agent that inhibits PAI-1 expression or PAI-1 activity. Another embodiment of the present invention is a method of treating a PAI-1-associated ocular disorder in a subject in need, comprising administering to the patient an effective amount of a composition comprising an agent that inhibits PAI-1 activity or expression.
摘要翻译： 本发明在一个实施方案中涉及用于治疗患者青光眼或升高的IOP的方法，包括向患者施用有效量的包含抑制PAI-1表达或PAI-1活性的药物的组合物。 本发明的另一个实施方案是治疗需要的受试者中PAI-1相关的眼部疾病的方法，包括向患者施用有效量的包含抑制PAI-1活性或表达的药物的组合物。
-
公开(公告)号：US20120115870A1
公开(公告)日：2012-05-10
申请号：US13348376
申请日：2012-01-11
申请人： Debra L. Fleenor , Iok-Hou Pang , Allan R. Shepard , Mark R. Hellberg , Peter G. Klimko , Abbot F. Clark
发明人： Debra L. Fleenor , Iok-Hou Pang , Allan R. Shepard , Mark R. Hellberg , Peter G. Klimko , Abbot F. Clark
IPC分类号： A61K31/5377 , C07D401/14 , A61K31/4439 , A61K31/437 , C07D471/04 , A61P27/02 , A61K31/506 , A61P27/06 , A61K31/519 , C07D417/12 , A61K31/495 , C07D413/12 , C07D413/14 , C12Q1/02 , C07D405/14
CPC分类号： G01N33/5008 , A61K31/357 , A61K31/381 , A61K31/4192 , A61K31/4196 , A61K31/44 , A61K31/4439 , A61K31/444 , A61K31/47 , A61K31/4709 , A61K31/4745 , A61K31/506 , A61K31/519 , A61K31/5375 , A61K31/5377 , A61K45/06 , G01N33/5023 , G01N33/5044 , A61K2300/00
摘要： An ophthalmic pharmaceutical composition useful in the treatment of glaucoma and control of intraocular pressure comprising an effective amount of a selective modulator of ALK5 receptor activity is disclosed. Also disclosed is a method of treating glaucoma and controlling intraocular pressure comprising applying a therapeutically effective amount of a pharmaceutical composition comprising a selective modulator of ALK5 receptor activity to an affected eye of a patient.
摘要翻译： 公开了一种可用于治疗青光眼和控制眼内压的眼用药物组合物，其包含有效量的ALK5受体活性的选择性调节剂。 还公开了一种治疗青光眼并控制眼内压的方法，其包括将治疗有效量的包含ALK5受体活性的选择性调节剂的药物组合物施用于患者的受影响的眼睛。
-
3.发明申请PAI-1 EXPRESSION AND ACTIVITY INHIBITORS FOR THE TREATMENT OF OCULAR DISORDERS 审中-公开PAI-1表达和活化抑制剂治疗眼病公开(公告)号：US20110105574A1
公开(公告)日：2011-05-05
申请号：US13006984
申请日：2011-01-14
IPC分类号： A61K31/41 , A61K31/403 , A61P27/02
CPC分类号： A61K31/404 , A61K31/19 , A61K31/192 , A61K31/22 , A61K31/277 , A61K31/353 , A61K31/366 , A61K31/403 , A61K31/41 , A61K31/416 , A61K31/437 , A61K31/4436 , A61K31/4439 , A61K31/4965 , A61K31/497 , A61K38/16
摘要： The invention concerns in one embodiment a method for treating glaucoma or elevated IOP in a patient comprising administering to the patient an effective amount of a composition comprising an agent that inhibits PAI-1 expression or PAI-1 activity. Another embodiment of the present invention is a method of treating a PAI-1-associated ocular disorder in a subject in need, comprising administering to the patient an effective amount of a composition comprising an agent that inhibits PAI-1 activity or expression.
摘要翻译： 本发明在一个实施方案中涉及用于治疗患者青光眼或升高的IOP的方法，包括向患者施用有效量的包含抑制PAI-1表达或PAI-1活性的药物的组合物。 本发明的另一个实施方案是治疗需要的受试者中PAI-1相关的眼部疾病的方法，包括向患者施用有效量的包含抑制PAI-1活性或表达的药物的组合物。
-
公开(公告)号：US20110098314A1
公开(公告)日：2011-04-28
申请号：US12941639
申请日：2010-11-08
IPC分类号： A61K31/505 , A61K31/351 , A61K31/22 , A61K31/404 , A61K31/40 , A61K31/47 , A61P27/02
CPC分类号： A61K31/00 , A61K31/225 , A61K31/366 , A61K31/401
摘要： The use of HMG-CoA reductase inhibitors (e.g., statins) to treat glaucoma, control intraocular pressure, preserve the trabecular meshwork, protect against ocular neurodegeneration and/or protect against glaucomatous retinopathy is described. The preferred HMG-CoA reductase inhibitors, which are statins having an RI value of 0.2 to 0.7 (e.g., pravastatin), are administered via topical application to the affected eye(s) of the patient.
摘要翻译： 描述了使用HMG-CoA还原酶抑制剂（例如他汀类药物）来治疗青光眼，控制眼内压，保留小梁网，防止眼神经变性和/或防止青光眼性视网膜病变。 优选的HMG-CoA还原酶抑制剂，其为RI值为0.2至0.7的他汀类（例如，普伐他汀），通过局部施用施用于患者的受影响的眼睛。
-
5.发明申请ANTAGONISTS OF ENDOTHELIAL DIFFERENTIATION GENE SUBFAMILY 3 (EDG-3, S1P3) RECEPTORS FOR PREVENTION AND TREATMENT OF OCULAR DISORDERS 审中-公开内分泌基因亚型3（EDG-3，S1P3）受体，用于预防和治疗眼部疾病的拮抗剂公开(公告)号：US20100183629A1
公开(公告)日：2010-07-22
申请号：US12749331
申请日：2010-03-29
申请人： Debra L. Fleenor , Allan R. Shepard , Iok-Hou Pang
发明人： Debra L. Fleenor , Allan R. Shepard , Iok-Hou Pang
IPC分类号： A61K39/395 , A61K38/02 , A61K31/426 , A61K31/54 , A61K31/661 , A61K31/167 , A61K31/17 , A61P9/12 , A61P27/02 , A61P27/06
CPC分类号： A61K31/17 , A61K31/426 , A61K31/54
摘要： Antagonists of S1P3 (Edg-3) receptors are provided for attenuation of Smad signaling in a method of down-regulation of receptor signaling and downstream decreased production of connective tissue growth factor in ocular disorders involving CTGF accumulation. Ocular disorders involving inappropriate CTGF accumulation include ocular hypertension, glaucoma, glaucomatous retinopathy, optic neuropathy, macular degeneration, diabetic retinopathy, choroidal neovascularization, proliferative vitreoretinopathy and ocular wound healing, for example. Such disorders are treated by administering antagonists of the present invention.
摘要翻译： 提供了S1P3（Edg-3）受体的拮抗剂，用于在受体信号下调的方法中减弱Smad信号，并且下游减少涉及CTGF积聚的眼部疾病中结缔组织生长因子的产生。 涉及不适当的CTGF积聚的眼部疾病包括例如眼高压，青光眼，青光眼性视网膜病变，视神经病变，黄斑变性，糖尿病性视网膜病变，脉络膜新生血管形成，增生性玻璃体视网膜病变和眼部伤口愈合。 通过施用本发明的拮抗剂治疗此类病症。
-
公开(公告)号：US20110160210A1
公开(公告)日：2011-06-30
申请号：US13042848
申请日：2011-03-08
申请人： Debra L. Fleenor , Iok-Hou Pang , Allan R. Shapard , Mark R. Hellberg , Abbot F. Clark , Peter G. Klimko
发明人： Debra L. Fleenor , Iok-Hou Pang , Allan R. Shapard , Mark R. Hellberg , Abbot F. Clark , Peter G. Klimko
IPC分类号： A61K31/5377 , A61P27/06 , C07D405/14 , A61K31/4439 , C12Q1/02 , C07D401/14 , A61K31/4709 , C07D487/04 , C07D471/04 , A61K31/4375 , A61K31/506 , A61K31/437 , A61K31/519 , A61K31/498 , C07D413/14
CPC分类号： G01N33/5008 , A61K31/357 , A61K31/381 , A61K31/4192 , A61K31/4196 , A61K31/44 , A61K31/4439 , A61K31/444 , A61K31/47 , A61K31/4709 , A61K31/4745 , A61K31/506 , A61K31/519 , A61K31/5375 , A61K31/5377 , A61K45/06 , G01N33/5023 , G01N33/5044 , A61K2300/00
摘要： An ophthalmic pharmaceutical composition useful in the treatment of glaucoma and control of intraocular pressure comprising an effective amount of a selective modulator of ALK5 receptor activity is disclosed. Also disclosed is a method of treating glaucoma and controlling intraocular pressure comprising applying a therapeutically effective amount of a pharmaceutical composition comprising a selective modulator of ALK5 receptor activity to an affected eye of a patient.
摘要翻译： 公开了一种可用于治疗青光眼和控制眼内压的眼用药物组合物，其包含有效量的ALK5受体活性的选择性调节剂。 还公开了一种治疗青光眼并控制眼内压的方法，其包括将治疗有效量的包含ALK5受体活性的选择性调节剂的药物组合物施用于患者的受影响的眼睛。
-
7.发明申请AGENTS WHICH REGULATE, INHIBIT, OR MODULATE THE ACTIVITY AND/OR EXPRESSION OF CONNECTIVE TISSUE GROWTH FACTOR (CTGF) AS A UNIQUE MEANS TO BOTH LOWER INTRAOCULAR PRESSURE AND TREAT GLAUCOMATOUS RETINOPATHIES/OPTIC NEUROPATHIES 审中-公开代理，禁止或调节连接性组织生长因子（CTGF）的活动和/或表达，作为双重下降的压力和治疗玻璃体积反射/视神经病变的独特手段公开(公告)号：US20110092523A1
公开(公告)日：2011-04-21
申请号：US12970662
申请日：2010-12-16
IPC分类号： A61K31/52 , A61K31/4439 , A61P27/02
CPC分类号： A61K31/4439 , A61K31/202 , A61K31/426 , A61K31/427 , A61K31/519 , A61K31/52
摘要： The present invention provides a method for lowering intraocular pressure and providing neuroprotection to a patient in need thereof by administering a therapeutically effective amount of at least one non-nucleotide or non-protein agent that inhibits expression and/or signaling of connective tissue growth factor (CTGF).
摘要翻译： 本发明提供了一种通过施用治疗有效量的至少一种抑制结缔组织生长因子的表达和/或信号转导的非核苷酸或非蛋白质试剂来降低眼内压并向有需要的患者提供神经保护作用的方法 CTGF）。
-
8.发明申请AGENTS WHICH REGULATE, INHIBIT, OR MODULATE THE ACTIVITY AND/OR EXPRESSION OF CONNECTIVE TISSUE GROWTH FACTOR (CTGF) AS A UNIQUE MEANS TO BOTH LOWER INTRAOCULAR PRESSURE AND TREAT GLAUCOMATOUS RETINOPATHIES/OPTIC NEUROPATHIES 审中-公开代理，禁止或调节连接性组织生长因子（CTGF）的活动和/或表达，作为双重下降的压力和治疗玻璃体积反射/视神经病变的独特手段公开(公告)号：US20080176964A1
公开(公告)日：2008-07-24
申请号：US12024821
申请日：2008-02-01
CPC分类号： A61K31/4439 , A61K31/202 , A61K31/426 , A61K31/427 , A61K31/519 , A61K31/52
摘要： The present invention provides a method for lowering intraocular pressure and providing neuroprotection to a patient in need thereof by administering a therapeutically effective amount of at least one non-nucleotide or non-protein agent that inhibits expression and/or signaling of connective tissue growth factor (CTGF).
摘要翻译： 本发明提供了一种通过施用治疗有效量的至少一种抑制结缔组织生长因子的表达和/或信号转导的非核苷酸或非蛋白质试剂来降低眼内压并向有需要的患者提供神经保护作用的方法 CTGF）。
-
9.发明授权Agents which regulate, inhibit, or modulate the activity and/or expression of connective tissue growth factor (CTGF) as a unique means to both lower intraocular pressure and treat glaucomatous retinopathies/optic neuropathies 失效调节，抑制或调节结缔组织生长因子（CTGF）的活性和/或表达的作为降低眼内压和治疗青光眼性视网膜病变/视神经病变的独特手段的药剂公开(公告)号：US07351407B2
公开(公告)日：2008-04-01
申请号：US10510585
申请日：2003-04-18
IPC分类号： A61K31/74
CPC分类号： A61K31/4439 , A61K31/202 , A61K31/426 , A61K31/427 , A61K31/519 , A61K31/52
摘要： The present invention provides a method for lowering intraocular pressure and providing neuroprotection to a patient in need thereof by administering a therapeutically effective amount of at least one non-nucleotide or non-protein agent that inhibits expression and/or signaling of connective tissue growth factor (CTGF).
摘要翻译： 本发明提供了一种通过施用治疗有效量的至少一种抑制结缔组织生长因子的表达和/或信号转导的非核苷酸或非蛋白质试剂来降低眼内压并向有需要的患者提供神经保护作用的方法 CTGF）。
-
10.发明申请USE OF INHIBITORS OF JUN N-TERMINAL KINASES TO TREAT GLAUCOMA 审中-公开UN UN OF OF OF OF A A A A A A A A A A A A A A A A A公开(公告)号：US20120004274A1
公开(公告)日：2012-01-05
申请号：US13232410
申请日：2011-09-14
申请人： Debra L. Fleenor , Iok-Hou Pang
发明人： Debra L. Fleenor , Iok-Hou Pang
IPC分类号： A61K31/416 , A61P27/02
CPC分类号： A61K31/00 , A61K31/407 , A61K31/416 , A61K31/506 , A61K31/553
摘要： Compositions and methods for lowering IOP and/or providing neuroprotection are disclosed. The compositions and methods are particularly directed to the use inhibitors of Jun N-terminal kinases (JNK) to lower IOP and/or provide neuroprotection.
摘要翻译： 公开了降低IOP和/或提供神经保护作用的组合物和方法。 组合物和方法特别涉及Jun N末端激酶（JNK）用于降低IOP和/或提供神经保护作用的抑制剂。
-
-
-
-
-
-
-
-
-
搜索结果
16 条记录 (耗时 0.027 秒)
